EE668 Empagliflozin for the Treatment of Adult Patients With Symptomatic Chronic Heart Failure With Reduced Ejection Fraction (HFREF): A Cost-Effectiveness Analysis From the Italian NHS Perspective

Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.907
https://www.valueinhealthjournal.com/article/S1098-3015(22)03111-4/fulltext
Section Title :
Section Order : 10451
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03111-4&doi=10.1016/j.jval.2022.09.907
HEOR Topics :
Tags :
Regions :